Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Regulatory press release 2025-10-10

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026

Regulatory press release 2025-10-08

Xspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval

Regulatory press release 2025-09-30

New number of shares and votes in Xspray Pharma after new share issue

Regulatory press release 2025-09-11

Xspray’s rights issue oversubscribed – over-allotment issue increased and fully utilized

Regulatory press release 2025-08-26

First day of trading in subscription rights and BTAs moved to August 27

Regulatory press release 2025-08-25

Xspray publishes disclosure document regarding rights issue

Regulatory press release 2025-08-25

Xspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue

Regulatory press release 2025-08-15

Interim Report Second Quarter 2025

Regulatory press release 2025-08-15

Xspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing

Regulatory press release 2025-08-12

Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds

Show more

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com

We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our Privacy policy.I agree